Drug Trial Radar · NCT05712694
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
218
Actual
Start
Nov 29, 2023
Primary completion
May 25, 2026
Study completion May 25, 2026
Sponsor
- Lead sponsor
- Polaris GroupIndustry
- Sponsor type
- Industry
- First posted
- Feb 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Conditions
- Soft Tissue Sarcoma
Interventions
ADI PEG20Drug
Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
PlaceboOther
Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary End Point of PFSTime frame: Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).
Locations
30 sites in 3 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
USC Norris comprehensive cancer center
Los Angeles, California
Stanford University Medical Centre
Palo Alto, California
UCSF
San Francisco, California
UCLA
Santa Monica, California
University of Colorado Cancer Center/ CU Anschutz Medical Campus
Aurora, Colorado
Mayo Clinic Florida
Jacksonville, Florida
University of Miami/ Sylvester Comprehensive Cancer Center
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Northwestern
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
Mass General Brigham Cancer Center
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
NYU Langone Health
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke Cancer Institute
Durham, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Ohio State University Wexner Medical Center/ The James Cancer Hospital and Solove Research Institute
Columbus, Ohio
UPenn (Abramson Cancer Center, Pennsylvania Hospital)
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
University of Texas MD Anderson Cancer Center
Houston, Texas
Medical College of Wisconsin/ Froedtert Hospital
Milwaukee, Wisconsin
UHN - Princess Margaret Cancer Center (Ontario)
Toronto, Ontario, Canada
McGill University Health Centre (Quebec)
Montreal, Quebec, Canada
Chang Gung Medical Foundation Kaohsiung
Kaohsiung City, Niaosong District, Taiwan
National Taiwan University Hospital
Taipei, Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.